Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MLNR | O43193 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449044 | 0.87 | ALDH1A1 (0.56) | KMT2AMEN1POLBALDH1A1HTT | |
| SCHEMBL6829343 | 0.86 | MEN1 (0.45) | KMT2AMEN1POLBALDH1A1HTT | |
| SCHEMBL9185883 | 0.84 | KMT2A (0.56) | KMT2AMEN1POLBALDH1A1HTT | |
| SCHEMBL5983525 | 0.83 | LMNA (0.51) | KMT2AMEN1POLBALDH1A1HTT | |
| SCHEMBL9475296 | 0.82 | MEN1 (0.44) | KMT2AMEN1POLBALDH1A1HTT | |
| SCHEMBL6489977 | 0.81 | ALDH1A1 (0.49) | KMT2AMEN1POLBALDH1A1HTT | |
| SCHEMBL471777 | 0.79 | ALDH1A1 (0.61) | KMT2AMEN1POLBALDH1A1HTT | |
| SCHEMBL30520310 | 0.79 | ALDH1A1 (0.61) | KMT2AMEN1POLBALDH1A1HTT | |
| SCHEMBL1137447 | 0.79 | CYP19A1 (0.59) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL250364 | 0.79 | KMT2A (0.49) | KMT2AMEN1POLBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339663-B1 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2338886-A2 | Naphthalene derivatives | Novartis AG (CH) | 2011-06-29 | — | — | EP | disclosed |
| US-7045533-B2 | Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout | NOVARTIS AG (CH) | 2006-05-16 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
| US-20040053890-A1 | Naphthalene derivatives | NOVARTIS AG (CH) | 2004-03-18 | — | — | US | disclosed |
| EP-1339663-A2 | NAPHTHALENE DERIVATIVES | Novartis AG (CH) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042248-A2 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053890-A1 | Naphthalene derivatives | CYP1A1, SULT1E1, CYP2F1 | KMT2A 4193/4885MEN1 760/4885POLB 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.